Yingsong Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yingsong Lin has a total of 376 co-authors. Here are the top co-authors by number of shared publications:
- Shogo Kikuchi
Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
21 shared publications Shogo Kikuchi
19 shared publicationsAkiko Tamakoshi
Department of Public Health, Hokkaido University Faculty of Medicine , Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638
14 shared publications- Keitaro Matsuo
Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan; Department of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
13 shared publications - Akiko Tamakoshi
Department of Public Health, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
12 shared publications - Yasushi Adachi
Sapporo Medical University 1 Division of Gastroenterology and Hepatology, Department of Internal Medicine Sapporo, Japan
12 shared publications
Latest Publications
- 4 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (11) , 1924-1929
Serum Soluble Fas Levels and Incidence of Biliary Tract Cancer in a Nested Case–Control Study
Background: Soluble Fas (sFas) plays multiple roles in tumorigenesis and cancer dissemination by avoiding apoptosis via connection to Fas ligand. We assessed associations of serum sFas levels with the incidence of extrahepatic biliary tract cancer (eBTC) in a prospective case–control study nested in the Japan Collaborative Cohort Study. Methods: A baseline survey was conducted from 1988 using blood samples from 39,242 individuals (35% of 110,585). Patients diagnosed with eBTC before the end of 1997 were regarded as cases. Odds ratios (OR) for cancer incidence associated with sFas were estimated by conditional logistic regression. Results: This study included 73 cases and 215 controls. Participants with high sFas showed an elevated risk of cancer (P trend = 0.01), and the third tertile of sFas showed a higher risk compared with the first tertile [OR, 3.27; 95% confidence interval (CI), 1.37–7.80]. In both gallbladder and extrahepatic bile duct cancers (n = 33 and 40, respectively), high sFas was associated with elevated risk (P trend = 0.04 and 0.02, respectively). In women and the nonelderly, subjects in the highest tertiles showed a higher cancer risk. Limiting subjects to those followed for over 2 years, high sFas was related to cancer risk (P trend = 0.02), and the third tertile showed a higher risk compared with the first (OR, 3.03; 95% CI, 1.14–8.07). Conclusions: High serum sFas may be related to future risk of eBTC. Impact: These findings highlight the need for additional studies of this biomarker in large prospective cohorts and through integrated analysis involving other cohorts.
- 4 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (11) , 1924-1929
Serum Soluble Fas Levels and Incidence of Biliary Tract Cancer in a Nested Case–Control Study
Background: Soluble Fas (sFas) plays multiple roles in tumorigenesis and cancer dissemination by avoiding apoptosis via connection to Fas ligand. We assessed associations of serum sFas levels with the incidence of extrahepatic biliary tract cancer (eBTC) in a prospective case–control study nested in the Japan Collaborative Cohort Study. Methods: A baseline survey was conducted from 1988 using blood samples from 39,242 individuals (35% of 110,585). Patients diagnosed with eBTC before the end of 1997 were regarded as cases. Odds ratios (OR) for cancer incidence associated with sFas were estimated by conditional logistic regression. Results: This study included 73 cases and 215 controls. Participants with high sFas showed an elevated risk of cancer (P trend = 0.01), and the third tertile of sFas showed a higher risk compared with the first tertile [OR, 3.27; 95% confidence interval (CI), 1.37–7.80]. In both gallbladder and extrahepatic bile duct cancers (n = 33 and 40, respectively), high sFas was associated with elevated risk (P trend = 0.04 and 0.02, respectively). In women and the nonelderly, subjects in the highest tertiles showed a higher cancer risk. Limiting subjects to those followed for over 2 years, high sFas was related to cancer risk (P trend = 0.02), and the third tertile showed a higher risk compared with the first (OR, 3.03; 95% CI, 1.14–8.07). Conclusions: High serum sFas may be related to future risk of eBTC. Impact: These findings highlight the need for additional studies of this biomarker in large prospective cohorts and through integrated analysis involving other cohorts.
- Open Access
- 17 August 2026
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 73
Infection-driven cancers in Asia: implications from epidemiological transitions
- 17 August 2026
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 73
Open AccessInfection-driven cancers in Asia: implications from epidemiological transitions
- 14 July 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (11) , 2694-2704
Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer
Early detection of pancreatic cancer remains challenging, and reliable circulating biomarkers are needed to enable earlier diagnosis and improve clinical outcomes. We conducted a plasma proteomics study using the Olink Explore HT platform to identify novel biomarker candidates for early‐stage pancreatic cancer. The study included 42 patients with stage I–II pancreatic cancer and 43 matched controls. Plasma protein levels were quantified using the Olink Proximity Extension Assay, and differential abundance was assessed using Welch's t ‐test with correction for multiple testing. Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC). Among 5419 proteins analyzed, 982 showed significant differences between cases and controls. Carboxylesterase 3 (CES3) was the most significantly decreased protein, whereas leukocyte immunoglobulin‐like receptor B4 (LILRB4) was the most significantly increased protein; both demonstrated excellent diagnostic performance (AUC = 0.91). In addition, pancreatic polypeptide (PPY) showed markedly reduced levels in patients with tumors arising in the head of the pancreas, suggesting anatomical specificity. This comprehensive Olink‐based proteomic analysis identifies CES3 and LILRB4 as promising plasma biomarkers for early‐stage pancreatic cancer and highlights PPY as informative for tumor localization. These findings provide a valuable resource for biomarker discovery and support further validation of these candidates for noninvasive early detection and risk stratification.
- 14 July 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (11) , 2694-2704
Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer
Early detection of pancreatic cancer remains challenging, and reliable circulating biomarkers are needed to enable earlier diagnosis and improve clinical outcomes. We conducted a plasma proteomics study using the Olink Explore HT platform to identify novel biomarker candidates for early‐stage pancreatic cancer. The study included 42 patients with stage I–II pancreatic cancer and 43 matched controls. Plasma protein levels were quantified using the Olink Proximity Extension Assay, and differential abundance was assessed using Welch's t ‐test with correction for multiple testing. Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC). Among 5419 proteins analyzed, 982 showed significant differences between cases and controls. Carboxylesterase 3 (CES3) was the most significantly decreased protein, whereas leukocyte immunoglobulin‐like receptor B4 (LILRB4) was the most significantly increased protein; both demonstrated excellent diagnostic performance (AUC = 0.91). In addition, pancreatic polypeptide (PPY) showed markedly reduced levels in patients with tumors arising in the head of the pancreas, suggesting anatomical specificity. This comprehensive Olink‐based proteomic analysis identifies CES3 and LILRB4 as promising plasma biomarkers for early‐stage pancreatic cancer and highlights PPY as informative for tumor localization. These findings provide a valuable resource for biomarker discovery and support further validation of these candidates for noninvasive early detection and risk stratification.
- 20 February 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (6) , 689-694
Serum superoxide dismutase activity and risk of esophageal cancer in a nested case–control study
Superoxide dismutase (SOD) is an antioxidant enzyme that acts to degrade superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and the incidence of esophageal cancer in a case–control study nested in the Japan Collaborative Cohort (JACC) Study. At baseline, 39 242 subjects donated serum samples. Participants who were diagnosed with esophageal cancer during follow-up were regarded as cases. Conditional logistic regression models were used to evaluate odds ratios (ORs) for esophageal cancer incidence associated with serum SOD activity. The present study included 27 cases and 80 controls. Serum SOD activity was associated with risk of esophageal cancer (P for trend = .040) and the third tertile of SOD level showed the highest risk compared to the first (OR = 7.41, 95% confidence interval [CI] = 1.14–48.35). Limiting subjects to those followed-up over 3 years, all trends remained unchanged (P for trend = .044), with the third tertile still showing the highest risk compared to the first (OR = 7.63, 95% CI = 1.06–55.23). Our findings suggest that serum SOD activity may be associated with the risk of esophageal cancer.
- 20 February 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (6) , 689-694
Serum superoxide dismutase activity and risk of esophageal cancer in a nested case–control study
Superoxide dismutase (SOD) is an antioxidant enzyme that acts to degrade superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and the incidence of esophageal cancer in a case–control study nested in the Japan Collaborative Cohort (JACC) Study. At baseline, 39 242 subjects donated serum samples. Participants who were diagnosed with esophageal cancer during follow-up were regarded as cases. Conditional logistic regression models were used to evaluate odds ratios (ORs) for esophageal cancer incidence associated with serum SOD activity. The present study included 27 cases and 80 controls. Serum SOD activity was associated with risk of esophageal cancer (P for trend = .040) and the third tertile of SOD level showed the highest risk compared to the first (OR = 7.41, 95% confidence interval [CI] = 1.14–48.35). Limiting subjects to those followed-up over 3 years, all trends remained unchanged (P for trend = .044), with the third tertile still showing the highest risk compared to the first (OR = 7.63, 95% CI = 1.06–55.23). Our findings suggest that serum SOD activity may be associated with the risk of esophageal cancer.
- Open Access
- 19 February 2026
- Published by Wiley in Cancer Science
- Vol. 117 (5) , 1446-1454
Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study
The association between body mass index (BMI) and pancreatic cancer remains elusive in Asian populations. Clarifying the causal relationship between type 2 diabetes (T2D) and pancreatic cancer warrants triangulation of evidence, with Mendelian Randomization (MR) providing a robust approach. A two‐sample, multivariable MR analysis was performed to investigate the associations between BMI, T2D, and pancreatic cancer risk in the Japanese population. Single nucleotide polymorphisms (SNPs) associated with BMI and T2D were selected from the Genome‐Wide Association Study (GWAS) Catalog, and summary statistics for pancreatic cancer were derived from our previous GWAS in the Japanese population. MR analyses were performed using a random‐effects inverse variance‐weighted (IVW) method as well as sensitivity analyses. Genetic predisposition to T2D, assessed using 891 SNPs, was associated with increased pancreatic cancer risk (IVW odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.08–1.25 per 1‐unit increase in the ln odds of T2D). MR‐Egger and weighted median MR analyses yielded similar results. By contrast, genetically indexed BMI showed no association with pancreatic cancer risk (IVW OR: 1.00; 95% CI: 0.95–1.04 per 1 kg/m 2 increase). The association between T2D and pancreatic cancer remained significant after adjusting for BMI (OR: 1.15; 95% CI: 1.07–1.24), while BMI was not significant in univariable or multivariable analyses. Our MR study supports a modest causal association of T2D, independent of BMI, with pancreatic cancer risk.
- 19 February 2026
- Published by Wiley in Cancer Science
- Vol. 117 (5) , 1446-1454
Open AccessAssociations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study
The association between body mass index (BMI) and pancreatic cancer remains elusive in Asian populations. Clarifying the causal relationship between type 2 diabetes (T2D) and pancreatic cancer warrants triangulation of evidence, with Mendelian Randomization (MR) providing a robust approach. A two‐sample, multivariable MR analysis was performed to investigate the associations between BMI, T2D, and pancreatic cancer risk in the Japanese population. Single nucleotide polymorphisms (SNPs) associated with BMI and T2D were selected from the Genome‐Wide Association Study (GWAS) Catalog, and summary statistics for pancreatic cancer were derived from our previous GWAS in the Japanese population. MR analyses were performed using a random‐effects inverse variance‐weighted (IVW) method as well as sensitivity analyses. Genetic predisposition to T2D, assessed using 891 SNPs, was associated with increased pancreatic cancer risk (IVW odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.08–1.25 per 1‐unit increase in the ln odds of T2D). MR‐Egger and weighted median MR analyses yielded similar results. By contrast, genetically indexed BMI showed no association with pancreatic cancer risk (IVW OR: 1.00; 95% CI: 0.95–1.04 per 1 kg/m 2 increase). The association between T2D and pancreatic cancer remained significant after adjusting for BMI (OR: 1.15; 95% CI: 1.07–1.24), while BMI was not significant in univariable or multivariable analyses. Our MR study supports a modest causal association of T2D, independent of BMI, with pancreatic cancer risk.
- 18 February 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (2)
Attributable fraction and interaction of tobacco smoking and alcohol drinking on the risk of head and neck cancer: a pooled analysis of 11 prospective cohort studies in Japan
Background: Tobacco smoking and alcohol drinking are major risk factors for head and neck cancer (HNC), but their interaction effects have not been investigated in the Japanese population. Methods: We conducted a pooled analysis using data from 11 prospective cohorts in Japan, covering a total of 434 431 participants with 5 969 082 person-years of follow-up. Cox proportional hazards model analyses were performed separately in each cohort. Interactions and population-attributable fractions (PAFs) were estimated through meta-analyses. Results: During follow-up, 1835 incidents of HNC were newly identified. Both smoking and drinking habits significantly increased HNC risk. Subsite analysis showed that smoking increased risk in several subsites, while drinking was associated with hypopharyngeal cancer only. The multiplicative interaction was 1.55 [95% confidence interval (CI): 1.12–2.14] and the additive interaction (relative excess risk due to interaction) was 0.87 (95% CI: 0.42–1.36). Among men, PAFs were 0.414 for smoking and 0.336 for drinking, while the combined PAF was 0.469. Subsite-specific analysis showed larger PAFs of smoking in the nasopharynx and larynx, and larger PAFs of drinking in the oral cavity and hypopharynx. Conclusion: Tobacco smoking and alcohol drinking interact to increase the risk of HNC in the Japanese population. The attributable fraction of each factor differs by subsite. These findings may aid the development of future preventive strategies for HNC.
- 18 February 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (2)
Attributable fraction and interaction of tobacco smoking and alcohol drinking on the risk of head and neck cancer: a pooled analysis of 11 prospective cohort studies in Japan
Background: Tobacco smoking and alcohol drinking are major risk factors for head and neck cancer (HNC), but their interaction effects have not been investigated in the Japanese population. Methods: We conducted a pooled analysis using data from 11 prospective cohorts in Japan, covering a total of 434 431 participants with 5 969 082 person-years of follow-up. Cox proportional hazards model analyses were performed separately in each cohort. Interactions and population-attributable fractions (PAFs) were estimated through meta-analyses. Results: During follow-up, 1835 incidents of HNC were newly identified. Both smoking and drinking habits significantly increased HNC risk. Subsite analysis showed that smoking increased risk in several subsites, while drinking was associated with hypopharyngeal cancer only. The multiplicative interaction was 1.55 [95% confidence interval (CI): 1.12–2.14] and the additive interaction (relative excess risk due to interaction) was 0.87 (95% CI: 0.42–1.36). Among men, PAFs were 0.414 for smoking and 0.336 for drinking, while the combined PAF was 0.469. Subsite-specific analysis showed larger PAFs of smoking in the nasopharynx and larynx, and larger PAFs of drinking in the oral cavity and hypopharynx. Conclusion: Tobacco smoking and alcohol drinking interact to increase the risk of HNC in the Japanese population. The attributable fraction of each factor differs by subsite. These findings may aid the development of future preventive strategies for HNC.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Background:Soluble Fas (sFas) plays various roles in carcinogenesis and tumor dissemination by preventing apoptosis via binding to Fas ligand. We analyzed associations of serum sFas levels with the incidence of liver cancer in a prospective case–control study nested in the Japan Collaborative Cohort Study.Methods:A baseline survey was conducted from 1988, with blood samples obtained from 39,242 subjects. Patients diagnosed with liver cancer were regarded as cases. Two or three controls were selected and matched for sex, age, and geographic area. Conditional logistic regression was used to estimate ORs for cancer incidence associated with sFas.Results:This study contained 86 cases and 249 controls. After controlling for alcohol intake, body mass index, smoking, and hepatitis viral infection, participants with high sFas showed elevated risk of cancer (Ptrend = 0.003) and the third tertile of sFas showed a higher risk compared with the first tertile [OR, 3.53; 95% confidence interval (CI), 1.28–9.69]. In hepatocellular carcinoma, high sFas was associated with elevated risk (Ptrend < 0.001). In men and the elderly, subjects in the highest tertiles showed higher cancer risk. Limiting subjects to those followed for 3 years, high sFas was related to liver cancer risk (Ptrend = 0.033) and the third tertile showed a higher risk compared with the first (OR, 2.94; 95% CI, 0.94–9.14).Conclusions:High serum sFas may be related to future risk of liver cancer.Impact:Our findings highlight this biomarker for further analysis in pooled investigations with different/larger prospective cohorts.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Background:Soluble Fas (sFas) plays various roles in carcinogenesis and tumor dissemination by preventing apoptosis via binding to Fas ligand. We analyzed associations of serum sFas levels with the incidence of liver cancer in a prospective case–control study nested in the Japan Collaborative Cohort Study.Methods:A baseline survey was conducted from 1988, with blood samples obtained from 39,242 subjects. Patients diagnosed with liver cancer were regarded as cases. Two or three controls were selected and matched for sex, age, and geographic area. Conditional logistic regression was used to estimate ORs for cancer incidence associated with sFas.Results:This study contained 86 cases and 249 controls. After controlling for alcohol intake, body mass index, smoking, and hepatitis viral infection, participants with high sFas showed elevated risk of cancer (Ptrend = 0.003) and the third tertile of sFas showed a higher risk compared with the first tertile [OR, 3.53; 95% confidence interval (CI), 1.28–9.69]. In hepatocellular carcinoma, high sFas was associated with elevated risk (Ptrend < 0.001). In men and the elderly, subjects in the highest tertiles showed higher cancer risk. Limiting subjects to those followed for 3 years, high sFas was related to liver cancer risk (Ptrend = 0.033) and the third tertile showed a higher risk compared with the first (OR, 2.94; 95% CI, 0.94–9.14).Conclusions:High serum sFas may be related to future risk of liver cancer.Impact:Our findings highlight this biomarker for further analysis in pooled investigations with different/larger prospective cohorts.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Supplementary Table 3: Summary of sFas levels by sex and smoking habit in this case and control groups
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Supplementary Table 3: Summary of sFas levels by sex and smoking habit in this case and control groups
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Supplementary Table 2: Odds ratios and 95% confidence intervals for liver cancer with reference to serum sFas among subgroups
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Supplementary Table 2: Odds ratios and 95% confidence intervals for liver cancer with reference to serum sFas among subgroups
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Supplementary Table 1: Odds ratios and 95% confidence intervals for HCC with reference to serum sFas among subgroups
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Serum Soluble Fas Levels and Incidence of Liver Cancer in Nested Case–Control Study
Supplementary Table 1: Odds ratios and 95% confidence intervals for HCC with reference to serum sFas among subgroups